Arcutis Biotherapeutics (ARQT) Competitors $9.26 -0.67 (-6.75%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARQT vs. INVA, KNSA, OCUL, PHAT, ORIC, BHVN, BBIO, CRNX, TGTX, and RAREShould you be buying Arcutis Biotherapeutics stock or one of its competitors? The main competitors of Arcutis Biotherapeutics include Innoviva (INVA), Kiniksa Pharmaceuticals (KNSA), Ocular Therapeutix (OCUL), Phathom Pharmaceuticals (PHAT), ORIC Pharmaceuticals (ORIC), Biohaven (BHVN), BridgeBio Pharma (BBIO), Crinetics Pharmaceuticals (CRNX), TG Therapeutics (TGTX), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical preparations" industry. Arcutis Biotherapeutics vs. Innoviva Kiniksa Pharmaceuticals Ocular Therapeutix Phathom Pharmaceuticals ORIC Pharmaceuticals Biohaven BridgeBio Pharma Crinetics Pharmaceuticals TG Therapeutics Ultragenyx Pharmaceutical Innoviva (NASDAQ:INVA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability. Which has stronger valuation & earnings, INVA or ARQT? Innoviva has higher revenue and earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInnoviva$310.46M3.81$179.72M$0.6927.39Arcutis Biotherapeutics$59.61M18.18-$262.14M-$1.79-5.17 Do analysts rate INVA or ARQT? Arcutis Biotherapeutics has a consensus target price of $15.50, suggesting a potential upside of 67.39%. Given Arcutis Biotherapeutics' higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Innoviva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innoviva 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Arcutis Biotherapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is INVA or ARQT more profitable? Innoviva has a net margin of 18.31% compared to Arcutis Biotherapeutics' net margin of -140.97%. Innoviva's return on equity of 20.84% beat Arcutis Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Innoviva18.31% 20.84% 11.38% Arcutis Biotherapeutics -140.97%-119.11%-45.95% Do insiders and institutionals believe in INVA or ARQT? 99.1% of Innoviva shares are owned by institutional investors. 1.7% of Innoviva shares are owned by insiders. Comparatively, 9.5% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer INVA or ARQT? In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Innoviva. MarketBeat recorded 7 mentions for Arcutis Biotherapeutics and 5 mentions for Innoviva. Arcutis Biotherapeutics' average media sentiment score of 1.02 beat Innoviva's score of 0.91 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer INVA or ARQT? Innoviva received 241 more outperform votes than Arcutis Biotherapeutics when rated by MarketBeat users. However, 64.13% of users gave Arcutis Biotherapeutics an outperform vote while only 57.69% of users gave Innoviva an outperform vote. CompanyUnderperformOutperformInnovivaOutperform Votes30057.69% Underperform Votes22042.31% Arcutis BiotherapeuticsOutperform Votes5964.13% Underperform Votes3335.87% Which has more risk and volatility, INVA or ARQT? Innoviva has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. SummaryInnoviva beats Arcutis Biotherapeutics on 10 of the 18 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARQT vs. The Competition Export to ExcelMetricArcutis BiotherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.08B$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E Ratio-5.174.8266.7313.27Price / Sales18.18374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book6.919.636.455.92Net Income-$262.14M$154.43M$119.73M$225.73M7 Day Performance-14.42%-9.46%-5.13%-1.34%1 Month Performance-2.42%-7.27%-2.71%1.15%1 Year Performance353.92%28.13%31.08%24.02% Arcutis Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARQTArcutis Biotherapeutics2.0907 of 5 stars$9.26-6.7%$15.50+67.4%+374.9%$1.08B$59.61M-5.17150Positive NewsINVAInnoviva1.35 of 5 stars$20.12-0.3%N/A+38.5%$1.26B$352.75M29.16112News CoverageKNSAKiniksa Pharmaceuticals2.2751 of 5 stars$23.04+0.8%N/A+37.4%$1.66B$270.26M-164.56220OCULOcular Therapeutix4.0252 of 5 stars$10.96-1.3%N/A+340.4%$1.71B$58.44M-8.12267Analyst ForecastNews CoveragePHATPhathom Pharmaceuticals2.8188 of 5 stars$13.10-22.3%N/A+19.8%$780.63M$680,000.00-2.30110High Trading VolumeORICORIC Pharmaceuticals4.1718 of 5 stars$10.30+0.4%N/A+29.8%$726.58MN/A-5.8980Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap UpBHVNBiohaven3.811 of 5 stars$52.41-2.0%N/A+49.6%$4.95B$462.51M-5.73239Earnings ReportAnalyst ForecastNews CoverageBBIOBridgeBio Pharma4.6019 of 5 stars$26.12-3.6%N/A-17.8%$4.91B$9.30M-9.93400Analyst ForecastAnalyst RevisionNews CoverageCRNXCrinetics Pharmaceuticals3.5501 of 5 stars$60.01-1.1%N/A+93.1%$4.80B$4.01M-15.88210Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageTGTXTG Therapeutics4.6026 of 5 stars$30.74+6.7%N/A+162.3%$4.76B$233.66M-307.37290Insider SellingGap UpRAREUltragenyx Pharmaceutical4.6264 of 5 stars$50.73+0.7%N/A+14.9%$4.68B$434.25M-7.841,276Analyst Forecast Related Companies and Tools Related Companies INVA Competitors KNSA Competitors OCUL Competitors PHAT Competitors ORIC Competitors BHVN Competitors BBIO Competitors CRNX Competitors TGTX Competitors RARE Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARQT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
